Hoellwerth Magdalena, Brandlmaier Matthias, Koelblinger Peter
Department of Dermatology and Allergology, Paracelsus Medical University, Muellner Hauptstraße 48, 5020 Salzburg, Austria.
Cancers (Basel). 2024 Dec 29;17(1):68. doi: 10.3390/cancers17010068.
Basal cell carcinoma (BCC) accounts for 80% of skin cancer cases. Although mostly curable by simple excision, the treatment of advanced disease can be challenging, as curative surgery or radiotherapy may not always be feasible. The scope of this review is to summarize current knowledge on molecular mechanisms in BCC pathogenesis, to elaborate on the definition of advanced/difficult-to-treat BCC, and to outline systemic treatment options. Particularly, pivotal trial data of the approved hedgehog inhibitors (HHI) sonidegib and vismodegib are compared. Concluding, we provide an overview of novel, particularly neoadjuvant and combined treatment approaches, both with hedgehog and immune-checkpoint inhibitors.
基底细胞癌（BCC）占皮肤癌病例的80%。尽管大多数通过简单切除即可治愈，但晚期疾病的治疗可能具有挑战性，因为根治性手术或放疗并不总是可行的。本综述的范围是总结目前关于BCC发病机制中分子机制的知识，阐述晚期/难治性BCC的定义，并概述全身治疗方案。特别是，对已获批的刺猬信号通路抑制剂（HHI）索尼德吉和维莫德吉的关键试验数据进行了比较。最后，我们概述了新型的，特别是新辅助和联合治疗方法，包括使用刺猬信号通路抑制剂和免疫检查点抑制剂的治疗方法。
Zotero 插件
